Experience with BCG adjuvant immunotherapy in stage II malignant melanoma.
Three years experience with post operative BCG adjuvant immunotherapy in stage II malignant melanoma is reported. Compared to a historical control group (35 cases), 23 melanoma patients showed a significantly improved remission duration and survival rate. It appears that patients with weak initial BCG reactions, which become gradually positive after several immunizations, get more benefit from the adjuvant immunotherapy than do patients with strongly positive initial BCG reactions.
D000328:Adult; D001500:BCG Vaccine / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008207:Lymphatic Metastasis; D008297:Male; D008545:Melanoma / Q000276:immunology / Q000628:therapy*; D008875:Middle Aged; D012075:Remission, Spontaneous; D012878:Skin Neoplasms / Q000276:immunology / Q000628:therapy*; D013997:Time Factors; D014374:Tuberculin Test
D001500:BCG Vaccine